IL271470B2 - Plasminogen therapy in conditions associated with pai–1 overexpression - Google Patents

Plasminogen therapy in conditions associated with pai–1 overexpression

Info

Publication number
IL271470B2
IL271470B2 IL271470A IL27147019A IL271470B2 IL 271470 B2 IL271470 B2 IL 271470B2 IL 271470 A IL271470 A IL 271470A IL 27147019 A IL27147019 A IL 27147019A IL 271470 B2 IL271470 B2 IL 271470B2
Authority
IL
Israel
Prior art keywords
plasminogen
pai
disease
use according
subject
Prior art date
Application number
IL271470A
Other languages
English (en)
Hebrew (he)
Other versions
IL271470B1 (en
IL271470A (en
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of IL271470A publication Critical patent/IL271470A/en
Publication of IL271470B1 publication Critical patent/IL271470B1/en
Publication of IL271470B2 publication Critical patent/IL271470B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL271470A 2017-06-23 2018-06-22 Plasminogen therapy in conditions associated with pai–1 overexpression IL271470B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
PCT/IB2018/000655 WO2018234861A1 (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression

Publications (3)

Publication Number Publication Date
IL271470A IL271470A (en) 2020-01-30
IL271470B1 IL271470B1 (en) 2025-03-01
IL271470B2 true IL271470B2 (en) 2025-07-01

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271470A IL271470B2 (en) 2017-06-23 2018-06-22 Plasminogen therapy in conditions associated with pai–1 overexpression

Country Status (20)

Country Link
US (1) US11826404B2 (enExample)
EP (1) EP3641888B1 (enExample)
JP (1) JP2020524689A (enExample)
KR (1) KR20200019217A (enExample)
CN (1) CN110831668B (enExample)
AU (1) AU2018287316B2 (enExample)
BR (1) BR112019027229A2 (enExample)
CA (1) CA3068153A1 (enExample)
CL (1) CL2019003789A1 (enExample)
DK (1) DK3641888T3 (enExample)
ES (1) ES2965937T3 (enExample)
FI (1) FI3641888T3 (enExample)
IL (1) IL271470B2 (enExample)
MX (1) MX2019015741A (enExample)
MY (1) MY203136A (enExample)
RU (1) RU2020100080A (enExample)
SG (1) SG11201912813SA (enExample)
TW (1) TWI868051B (enExample)
WO (1) WO2018234861A1 (enExample)
ZA (1) ZA202000280B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
TW201822809A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療高脂血症的方法
EP4094775A4 (en) * 2020-02-06 2023-04-19 Talengen International Limited METHODS AND MEDICATIONS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS
JP2023518563A (ja) * 2020-03-24 2023-05-02 タレンゲン インターナショナル リミテッド パーキンソン病を治療する方法及び薬剤
TW202143999A (zh) * 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物
WO2021190558A1 (zh) * 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗阿尔茨海默病的方法和药物
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631786A1 (en) * 1993-07-02 1995-01-04 IMMUNO Aktiengesellschaft Lys - plasminogen in the prevention and treatment of ischemia and reperfusian injury
US20160200831A1 (en) * 2013-08-13 2016-07-14 Sanofi Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
WO2017081529A1 (en) * 2015-11-10 2017-05-18 Prometic Biotherapeutics, Ltd. Plasminogen dosage regimen for wound healing
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677473B1 (en) * 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
EP2056865B1 (en) * 2006-08-28 2013-12-25 Omnio Healer AB Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
CN101573134B (zh) * 2006-08-28 2013-03-06 李季男 抗感染候选药物
WO2018108161A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
CA3047170A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631786A1 (en) * 1993-07-02 1995-01-04 IMMUNO Aktiengesellschaft Lys - plasminogen in the prevention and treatment of ischemia and reperfusian injury
US20160200831A1 (en) * 2013-08-13 2016-07-14 Sanofi Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
WO2017081529A1 (en) * 2015-11-10 2017-05-18 Prometic Biotherapeutics, Ltd. Plasminogen dosage regimen for wound healing
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TROY LAUREN K., AND TAMERA J. CORTE:, THERAPY FOR IDIOPATHIC PULMONARY FIBROSIS: LESSONS FROM POOLED DATA ANALYSES, 31 December 2015 (2015-12-31) *

Also Published As

Publication number Publication date
CN110831668A (zh) 2020-02-21
WO2018234861A1 (en) 2018-12-27
EP3641888B1 (en) 2023-10-11
KR20200019217A (ko) 2020-02-21
MY203136A (en) 2024-06-10
RU2020100080A (ru) 2021-07-23
SG11201912813SA (en) 2020-01-30
DK3641888T3 (da) 2024-01-02
AU2018287316B2 (en) 2024-09-19
TWI868051B (zh) 2025-01-01
FI3641888T3 (fi) 2023-12-19
US11826404B2 (en) 2023-11-28
BR112019027229A2 (pt) 2020-07-07
IL271470B1 (en) 2025-03-01
CN110831668B (zh) 2024-04-12
CL2019003789A1 (es) 2020-07-10
RU2020100080A3 (enExample) 2021-11-02
MX2019015741A (es) 2020-11-11
ES2965937T3 (es) 2024-04-17
JP2020524689A (ja) 2020-08-20
TW201904990A (zh) 2019-02-01
ZA202000280B (en) 2021-08-25
CA3068153A1 (en) 2018-12-27
IL271470A (en) 2020-01-30
US20210330761A1 (en) 2021-10-28
AU2018287316A1 (en) 2020-02-06
EP3641888A1 (en) 2020-04-29
EP3641888A4 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
US11826404B2 (en) Plasminogen treatment of conditions associated with PAI-1 overexpression
Peng et al. Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for neuroprotection in stroke
Wang et al. Protective effect of peptide DR8 on bleomycin-induced pulmonary fibrosis by regulating the TGF-β/MAPK signaling pathway and oxidative stress
WO2015070619A1 (zh) 鸢尾素在制备预防心肌缺血再灌注损伤的药物中的应用
JP2009531036A (ja) Ｖｅｇｆ受容体融合タンパク質およびそれらの使用
WO2008091692A2 (en) Methods of diagnosing, treating, and preventing increased vascular permeability
Zhu et al. MMP-9 inhibition alleviates postoperative cognitive dysfunction by improving glymphatic function via regulating AQP4 polarity
CA3152346A1 (en) Methods of treatment for modifying hemodynamics
Kou et al. [Retracted] Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis
KR20130058669A (ko) 릴랙신을 사용한 아쿠아포린의 조절
Tang et al. Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a
Earle et al. Ubiquitin reduces fluid shifts after traumatic brain injury
Cavaglia et al. Increased transcription factor expression and permeability of the blood brain barrier associated with cardiopulmonary bypass in lambs
Griepke et al. Selective inhibition of soluble tumor necrosis factor signaling reduces abdominal aortic aneurysm progression
CN103038253A (zh) 作为用来稳定生物屏障的活性剂的肽
EP4471154A1 (en) Use of kinin or derivative thereof in treating vci, psci, or csvd
Wataya-Kaneda Tuberous sclerosis complex
WO1997035609A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
CN110511266B (zh) 一种小分子多肽及其用途
HK40029531A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
HK40029531B (en) Plasminogen treatment of conditions associated with pai-1 overexpression
Su et al. Overexpression of Corin ameliorates kidney fibrosis through Inhibition of Wnt/β-Catenin signaling in mice
US20200000939A1 (en) Method for creating a renal injury model to screen molecules for the treatment of renal injury
Jitsuiki et al. A case of blue rubber bleb nevus syndrome with Kasabach-Merritt syndrome and heart failure
WO2019048898A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION